OCS · Oculis Holding AG
$10.91
-3.54% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$0B
Trailing P/E
—
Forward P/E
-6.9
Dividend yield
—
Beta
0.23
Avg volume
0M
Employees
0K
Daily Change %
-3.54%
5 Days Change
-5.75%
10 Days Change
-6.37%
30 Days Change
-10.04%
60 Days Change
-15.85%
Month to Day Change
-5.83%
Year to Day Change
-42.56%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OCS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-14
Latest call per bank · past 12 months
JP Morgan
Overweight$20.00
+76.8% vs priceBank of America
Buy$29.00
+156.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | JP Morgan | Maintains | Overweight | $23.00 → $20.00 |
| 2026-08-05 | HC Wainwright & Co. | Maintains | Buy | $26.00 |
| 2026-06-03 | JP Morgan | Maintains | Overweight | $42.00 → $23.00 |
| 2026-06-02 | Baird | Maintains | Outperform | $49.00 → $38.00 |
| 2026-06-01 | Stifel | Maintains | Buy | $50.00 → $40.00 |
| 2026-06-01 | Guggenheim | Maintains | Buy | $75.00 → $45.00 |
| 2026-06-01 | Needham | Maintains | Buy | $46.00 → $38.00 |
| 2026-06-01 | HC Wainwright & Co. | Maintains | Buy | $47.00 → $26.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 26 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 12.2% below the 50-day MA ($12.43).
- Price vs 200-day MA: Trading 47.8% below the 200-day MA ($20.89).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.16) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($10.71).
OCS Price Chart
Loading chart for OCS…
Fundamentals
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.